- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - AZD1222 US Ph3 primary analysis confirms efficacy
AnnouncementREG - AstraZeneca PLC - AstraZeneca US vaccine trial met primary endpoint
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - AstraZeneca PLC - Divestment of Viela shareholding completed
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Designation of EU home member state
AnnouncementREG - AstraZeneca PLC - US court decision favours Symbicort patents
AnnouncementREG - AstraZeneca PLC - Further update on roxadustat US regulatory review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Voluntary withdrawal Imfinzi US bladder indication
AnnouncementREG - AstraZeneca PLC - Lynparza: IDMC recommend early analysis of OlympiA
AnnouncementREG - AstraZeneca PLC - Filing of Form 20-F with SEC
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Annual Financial Report
AnnouncementREG - AstraZeneca PLC - AstraZeneca Non-Executive Board changes
AnnouncementREG - AstraZeneca PLC - AZN: full-year 2020 results
AnnouncementREG - AstraZeneca PLC - Divestment of Crestor in Europe completed
AnnouncementREG - AstraZeneca PLC - Update on KESTREL Phase III trial for Imfinzi
Announcement